Total current assets 63,421,575 67,732,117
Capital assets, net 894,698 958,689
Intangible assets 26,531,541 26,185,155
-------------------------------------------------------------------------
90,847,814 94,875,961
-------------------------------------------------------------------------
-------------------------------------------------------------------------
LIABILITIES AND SHAREHOLDERS' EQUITY
Current
Accounts payable and accrued liabilities 1,549,717 1,576,190
Due to Elan Pharma International Limited 2,060,123 1,795,242
-------------------------------------------------------------------------
Total current liabilities 3,609,840 3,371,432
Deferred revenue 27,736,750 27,736,750
Leasehold inducement 77,166 80,024
-------------------------------------------------------------------------
Total liabilities 31,423,756 31,188,206
-------------------------------------------------------------------------
Shareholders' equity
Common shares 160,471,098 160,262,540
Contributed surplus 4,492,251 4,492,251
Stock options 3,654,276 3,093,735
Deficit (109,193,567) (104,160,771)
-------------------------------------------------------------------------
Total shareholders' equity 59,424,058 63,687,755
-------------------------------------------------------------------------
'/>"/>
| SOURCE Transition Therapeutics Inc. Copyright©2008 PR Newswire. All rights reserved |